Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-10-15
2010-12-07
Chong, Kimberly (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S024310, C536S024100
Reexamination Certificate
active
07846911
ABSTRACT:
Oligonucleotides directed against the hypoxia-inducible factor-1α (HIP-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
REFERENCES:
patent: 4857653 (1989-08-01), Colin et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5227400 (1993-07-01), Holton et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Yasutsugu et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5882914 (1999-03-01), Semenza
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 6030954 (2000-02-01), Wu
patent: 6706505 (2004-03-01), Han et al.
patent: 6770748 (2004-08-01), Imanishi et al.
patent: 6821724 (2004-11-01), Mittman et al.
patent: 2003/0032794 (2003-02-01), Koch et al.
patent: 2004/0002473 (2004-01-01), Kurrech et al.
patent: 2004/0220393 (2004-11-01), Ward et al.
patent: 0 253 739 (1989-10-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 93/18210 (1993-09-01), None
patent: WO 96/39426 (1996-12-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 99/48916 (1999-09-01), None
patent: WO 99/49065 (1999-09-01), None
patent: WO 00/56746 (2000-09-01), None
patent: WO 00/56748 (2000-09-01), None
patent: WO 00/64262 (2000-11-01), None
patent: WO 00/64262 (2000-11-01), None
patent: WO 00/66604 (2000-11-01), None
patent: WO 00/76497 (2000-12-01), None
patent: WO 00/78341 (2000-12-01), None
patent: WO 01/25248 (2001-04-01), None
patent: WO 02/28875 (2002-04-01), None
patent: WO 02/34291 (2002-05-01), None
patent: WO 02/094250 (2002-11-01), None
patent: WO 02/099104 (2002-12-01), None
patent: WO 03/006475 (2003-01-01), None
patent: WO 03/085110 (2003-10-01), None
patent: WO 03/095467 (2003-11-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2004/046160 (2004-06-01), None
patent: WO 2004/069991 (2004-08-01), None
patent: WO 2004/069992 (2004-08-01), None
Semenza, G. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, vol. 3, Oct. 2003, pp. 721-732.
Maxwell, P. The HIF Pathway in cancer. Seminars in Cell & Dev. Biology 2005, pp. 523-530.
U.S. Appl. No. 60/370,126, Albaek, C.
Acheampong et al., “Distribution of Brimonidine into Anterior and Posterior Tissues of Monkey, Rabbit, and Rat Eyes,”Drug Metabolism and Distribution, vol. 30, No. 4, pp. 421-429 (2002).
Andrew, et al., “Nickel requires hypoxia-inducible factor-1α, not redox signaling, to induce plasminogen activator inhibitor-1,” Am J. Physiol. Lung Cell Mol Physiol, vol. 281, pp. L607-L615 (2001).
Australian Government/IP Australia, Examiner's patent application No. 20033225495 dated Apr. 18, 2007.
Beaucage et al., “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,”Tetrahedron, vol. 48, No. 12, pp. 2223-2311 (1992).
Beaucage et al., 1993, “The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,”Tetrahedron, 49(28):6123-6194.
Brown et al., 1991, “In Oligonucleotides and Analogues. A Practical Approach,”Oxford: IRL 13-14.
Caniggia et al., “Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3” The Journal of Clinical Investigation, vol. 105, No. 5, pp. 577-587 (2000).
Caniggia et al., “Oxygen and Placental Development During the First Trimester: Implications for the Pathophysiology of Pre-eclampsia,” Placenta, 21, Supplement A, Trophoblast Research 14, pp. S25-S30 (2000).
Cao et al., “Vascular Endothelial Growth Factor C Induces Angiogenesis in vivo,”Proc. Nat. Acad. Sci., vol. 95, No. 24, pp. 14389-14394 (1998).
Chin, Andrew, “On the Preparation and Utilization Isolated and Purified Oligonucleotides,”University of North Carolina School of Law(2002).
Crooke, R.M., “In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides,”Antisense Res. and Application, vol. 131, pp. 103-140 (1997).
Dai et al., “Inhibition of Hypoxia Inducible Factor 1α Causes Oxygen-Independent Cytotoxicity and Induces p53 Independent Apoptosis in Glioblastoma Cells,”Int J. Radiat Oncol Biol Phys., vol. 55, No. 4, pp. 1027-1036 (2003).
Dass, Crispin R., “Vehicles for Oligonucleotide Delivery to Tumours, ”J Pharm Pharmacol., vol. 54, No. 1, pp. 3-27 (2002).
Distler et al., “Physiologic Responses to Hypoxia and Implications for Hypoxia-Inducible Factors in the Pathogenesis of Rheumatoid Arthritis,” Arthritis Rheum., vol. 50, No. 1, pp. 10-23 (2004).
Drutel et al., “Two splice variants of the hypoxia-inducible factor HIF-1α as potential dimerization partners of ARNT2 in neurons,” European Journal of Neuroscience, vol. 12, pp. 3701-3708 (2000).
Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes,” Nucleic Acids Research, vol. 25, No. 22, pp. 4429-4443 (1997).
Heid et al., “Real time Quantitative PCR,”Genome Res., vol. 6, No. 10, pp. 986-994 (1996).
Hoeg et al., “Specific down-regulation of hypoxia-inducible factor lα (HIF1α) in a human glioblastoma cell line by locked nucleic acid (LNA) antisense oli-gonucleotides,”American Association for Cancer Research, #4763, vol. 43, pp. 962 (2002).
Holmes et al., “Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer,”J. Natl. Cancer Inst., vol. 83, No. 24, pp. 1797-1805 (1991).
Holton et al., “First Total Synthesis of Taxol. 1. Functionalization of the B Ring,”J. Am. Chem. Soc., vol. 116, No. 4, pp. 1597-1598 (1994).
INPADOC Patent Family History for EP0253739 (A1), www.espacenet.com, No. 9, as it relates to A5 above, Jan. 29, 2009.
Japanese National Phase PCT Laid-Open Publication No. 2002-508944 (corresponding to W099/49065—B8 above).
Japanese Patent Office Official Action dated Oct. 17, 2008 for Japanese Application No. 2003-582288 corresponding to the above-referenced application.
Kakinuma et al., “Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1α Induced for Impaired Myocardial Energy Metabolism,”Circulation, vol. 103, pp. 2387-2394 (2001).
Kang et al., “Circulation, American Heart Association,” Database No. PX009015505, Vol. 104, No. 17, pp. 1157 (2001).
Kang et al., “An Antisense Oligonucleotide That Inhibits the Expression of Hypoxia-Inducible Factor-1α Alters Hypoxia-Induced Changes in Proliferation and Viability of Human Cardiac Fibroblasts,”Basic Science/Schientific Sessions, 11-57, pp. 274 (2001).
Kohn et al., “Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer,”J. Natl. Cancer Inst., vol. 86, No. 1, pp. 18-24 (1994).
Koshkin et al., “LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methycytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition,”Tetrahedron, vol. 54, pp. 3607-3630 (1998).
Koshkin et al., “A Simplified and Efficient Route to 2′-O, 4′-C-Methylene-Linked Bicyclic Ribonucleosides (Locked Nuclei
Hog Anja Molhart
Kristjansen Paul E. G.
Thrue Charlotte Albaek
Chong Kimberly
Dechert LLP
Enzon Pharmaceuticals, Inc.
Santaris Pharma A/S
LandOfFree
Oligomeric compounds for the modulation of HIF-1alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligomeric compounds for the modulation of HIF-1alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligomeric compounds for the modulation of HIF-1alpha... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184389